The most expensive part of a hospital bill may never touch the hospital at all.
A patient admitted for care has no way of knowing whether the price on a medical consumable reflects its actual cost or a markup fixed long before it ever reached the ward. That gap in information is, at its core, a public health issue.
A survey of hospital consumables in Maharashtra found an IV infusion set with a trade price of ₹11.05 carrying a printed MRP of ₹325 ; a markup of 2,841%. A syringe procured at ₹6.75 carried an MRP of ₹57.20. A catheter procured at ₹29.41 carried an MRP of ₹310.
These are not elective purchases. Patients cannot compare prices, seek alternatives, or question a number printed on a box while receiving care and the MRP itself is often fixed upstream by manufacturers and distributors, disconnected from the trade price by a wide, unexplained margin. The result is a system where the party bearing the cost has the least information to evaluate it.
The regulatory gap is structural: scheduled medicines are capped under the Drugs (Prices Control) Order, 2013. Most medical devices and consumables are not leaving both the pricing and the information around it almost entirely unmonitored.
A review of these findings and clear guidelines on the permissible gap between trade procurement price and declared MRP have been recommended to the Department of Pharmaceuticals and the NPPA ; a step toward closing not just a pricing gap, but the information gap patients are left to bear alone.
#PublicHealth #GoodGovernance #Leadership #TukaramMundhe
https://t.co/Ye9CVzr8qU
CSS officers have raised their voice—and the issue is now TRENDING on X in India! 📢🔥
Officers came together on social media to highlight the 8-year delay in the 4th CSS Cadre Review.
When those who help light the way for others are left in the dark, it truly is “चिराग़ तले अंधेरा।”
We now urge the Government to act and complete the 4th CSS Cadre Review urgently.
@PMOIndia@DoPTGoI@DrJitendraSingh
#ExpediteCSSCadreReview #चिरागतलेअंधेरा